BofA analyst Jason Gerberry lowered the firm’s price target on Immunovant (IMVT) to $38 from $45 and keeps a Buy rating on the shares. The firm ...

Guggenheim lowered the firm’s price target on Immunovant (IMVT) to $44 from $46 and keeps a Buy rating on the shares after having hosted ...

Fans don't think that the two colors in the Super Bowl 2025 logo — red and green — are a coincidence Skyler Caruso is a Writer and Reporter of PEOPLE Digital Entertainment. She joined PEOPLE ...

Immunovant, Inc. (NASDAQ:IMVT – Get Free Report)’s share price fell 5% on Thursday following a weaker than expected earnings announcement.The company traded as low as $21.71 and last traded at ...

KBC Group NV boosted its position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 60.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange ...

It’s show-me time for batoclimab, the FcRn-targeting antibody treatment from Immunovant and Roivant Sciences. A consequential Phase 3 study readout is coming before the end of the first quarter.

Immunovant, Inc. reported significant progress related to its lead asset IMVT-1402, having secured six Investigational New Drug applications and currently enrolling participants in pivotal studies ...

SEC Filings provided by EDGAR Online, Inc.

Immunovant, Inc. IMVT reported third-quarter fiscal 2025 net loss of 76 cents per share, wider than the Zacks Consensus Estimate of a loss of 73 cents. The reported figure is also wider than the ...

Of course, some criticize these modern logos as being copy-and-paste, minimalist and unoriginal. Those yearn to return to the unique logos of the 1990s and early 2000s, where the NFL used elements ...

In this article, we are going to take a look at where Immunovant, Inc. (NASDAQ:IMVT) stands against other biotech stocks with the biggest upside potential. While 2024 was a “challenging” year ...